Dyadic International Inc DYAI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DYAI is a good fit for your portfolio.
News
-
Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
-
Dyadic to Attend Industry Events in June
-
Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
-
Dyadic to Attend Industry and Investor Events in May
-
Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
Trading Information
- Previous Close Price
- $1.41
- Day Range
- $1.40–1.57
- 52-Week Range
- $1.28–2.67
- Bid/Ask
- $1.46 / $1.59
- Market Cap
- $45.32 Mil
- Volume/Avg
- 129,804 / 106,628
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 19.80
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 7
- Website
- https://www.dyadic.com
Comparables
Valuation
|
Metric
|
DYAI
|
EQRX
|
JANX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 10.02 | 0.97 | 3.48 |
Price/Sales | 19.80 | — | 276.71 |
Price/Cash Flow | — | — | — |
Price/Earnings
DYAI
EQRX
JANX
Financial Strength
|
Metric
|
DYAI
|
EQRX
|
JANX
|
|---|---|---|---|
Quick Ratio | 5.44 | 18.43 | 61.85 |
Current Ratio | 5.54 | 18.78 | 62.09 |
Interest Coverage | — | — | — |
Quick Ratio
DYAI
EQRX
JANX
Profitability
|
Metric
|
DYAI
|
EQRX
|
JANX
|
|---|---|---|---|
Return on Assets (Normalized) | −71.01% | −15.72% | −8.24% |
Return on Equity (Normalized) | −101.42% | −16.71% | −9.04% |
Return on Invested Capital (Normalized) | −91.23% | −21.31% | −12.64% |
Return on Assets
DYAI
EQRX
JANX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Jhwbcnkxg | Fjl | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Fsvfkxct | Rgdtsg | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hgytrrwv | Fnhcd | $118.7 Bil | |||
| Moderna Inc
MRNA
| Rztgchlbn | Jjjv | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Tpczkszzq | Jvfll | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Bmjgcrqz | Rjgz | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Cbxxqff | Yjxmt | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Qvrkylmw | Rwrtfdg | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Kxtlhgky | Smbg | $15.0 Bil | |||
| Incyte Corp
INCY
| Djqhfzvp | Mhjncv | $13.5 Bil |